A New Metabolic Lens to Advance Precision Therapies
Rheos leverages our unique understanding of cellular metabolism to identify key mechanisms in metabolic hubs – the metabolic pathways that drive immune cell dysfunction and disease. With our proprietary MetPM™ platform, we combine an unmatched knowledge base of metabolic hubs with experienced drug discovery and data analytics teams to bring innovation across the continuum of drug discovery and development.
Our MetPM platform generates and integrates hundreds of thousands of (and growing) data points from human immune cell genetics, epigenetics, transcriptomics and metabolomics, along with published patient data and decades of historical metabolism research. The Rheos team integrates this vast understanding of immunometabolism to discover novel drug targets, create new molecularly-targeted medicines, and identify molecular signatures for patient subsets.
Target Discovery Through Rheos Proprietary Toolkit
The foundation of our platform is the bioinformatic integration and comparison of genetic, transcriptomic, epigenomic and metabolomic datasets to create immunometabolism network maps. Our scientists use immunometabolism network maps to identify targets that simultaneously modulate multiple immune cell types to drive system-wide changes in immune function.
Matching Patients to Therapeutics to Enable Precision Medicine
Rheos’s platform gives us the ability to not only understand the fundamental metabolic drivers of immune cell differentiation, but also the aberrations in metabolic activity that contribute to persistent autoimmune and inflammatory diseases. Investigation of these pathways arm us with powerful tools to both understand diseases broadly, and to advance therapies which significantly improve response in biologically distinct patient subpopulations.